Epidemiology of co-existent overactive-underactive bladder (COUB) from results of the 2023 Japan Community Health Survey (JaCS 2023): its prevalence and impact on quality of life as well as health-care seeking behavior

Sekido N1, Mitsui T2, Masumori N3, Haga N4, Omae K5, Saito M6, Kubota Y7, Sakakibara R8, Yoshida M9, Takahashi S10

Research Type

Clinical

Abstract Category

Quality of Life / Patient and Caregiver Experiences

Abstract 802
Open Discussion ePosters
Scientific Open Discussion Session 108
Friday 25th October 2024
12:55 - 13:00 (ePoster Station 6)
Exhibit Hall
Overactive Bladder Underactive Bladder Quality of Life (QoL) Female Male
1. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Toho University Ohashi Medical Cente, 2. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, University of Yamanashi Graduate School of Medical Sciences, 3. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Sapporo Medical University School of Medicine, 4. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Fukuoka University, 5. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Fukushima Medical University Hospital, 6. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Kochi University, 7. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Nagoya City University Graduate School of Nursing, 8. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, 9) Neurology Clinic Tsudanuma and Dowakai Chiba Hospital, 9. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Tohoku University Graduate School of Medicine, 10. 1) Epidemiological Survey Executive Committee, the Japanese Continence Society, Nihon University School of Medicine
Presenter
N

Noritoshi Sekido

Links

Poster

Abstract

Hypothesis / aims of study
Co-existent overactive-underactive bladder (COUB) has been proposed as a term for the combination of overactive bladder (OAB) and underactive bladder (UAB) [1]. There are few studies on the epidemiology of COUB because there is no established definition of UAB. On the other hand, an EPIC study showed that OAB with additional voiding as well as postvoiding symptoms has a greater impact on patients’ lives than OAB without additional symptoms [2]. In this study, using the International Continence Society Working Group (ICS-WG) definition of UAB [3], we investigated the prevalence of OAB with UAB (COUB), OAB alone, UAB alone, and non-OAB/UAB by gender and age, and unveiled their impact on quality of life (QOL) as well as health care-seeking behavior. We hypothesized the increased prevalence of COUB with age, the poorest quality of life, and the highest physician visit rate in the COUB population among the four groups.
Study design, materials and methods
We conducted a large-scale nationwide epidemiological online survey of lower urinary tract symptoms in 6210 participants (3088 females and 3122 males) aged 20–99 years old who were selected by probability sampling based on the composition of the Japanese population. To determine the prevalence of each category, OAB and UAB were diagnosed by the OAB symptom score (urgency score ≥2 and total score ≥3) and the definition by the ICS-WG (participants with a slow urinary stream, hesitancy, and straining to void) [3], respectively. The prevalence of COUB in the OAB and UAB population was also examined. QOL was evaluated by a modified King’s Health Questionnaire. In addition, health care-seeking behavior was assessed. Chi-square and Cochran-Armitage tests were used for statistical analyses, and p <0.05 was considered statistically significant.
Results
The overall prevalences of COUB, OAB, UAB, and non-OAB/UAB were 4.3% (n = 135), 9.6% (n = 299), 5.0% (n = 155), and 81.1% (n = 2533) in men, and 1.6% (n = 50), 8.2% (n = 254), 2.4% (n = 73), and 87.8% (n = 2711) in women, respectively. The prevalence of all categories significantly increased with age (Figure 1A and B). The overall prevalence of COUB in the OAB population was 31.1% (135/434) and 16.4% (50/304) in men and women, respectively, and significantly increased with age only in women (Figure 1C). The overall prevalence of COUB in the UAB population was 46.6% (135/290) and 40.7% (50/123) in men and women, respectively, which significantly increased with age only in women (Figure 1D). In the COUB population, the impact on QOL rated as slight or more and the proportion of physician visits was the highest among the groups (Figure 2A to 2D).
Interpretation of results
The prevalence of COUB increased with age. However, the prevalence of COUB with age in the OAB and UAB population differed between men and women. This suggests that gender differences should be kept in mind when considering the pathophysiology of COUB. Consistent with the results of EPIC study [2], COUB adversely affects participants’ QOL to a substantial degree, which should be associated with the higher physician visit rate than in other groups. Major limitations of this study are that the incidence as well as remission rates of OAB and UAB were not taken into account because it was a cross-sectional study in nature, and a transition rate from OAB to UAB, if the phenomenon exists, has not been established.
Concluding message
In this large-scale cross-sectional study, the prevalence of COUB increased with age, but certain gender differences may exist. Further longitudinal studies focusing not only on OAB but also on UAB are required to elucidate the precise epidemiological aspects of COUB. This study highlighted that COUB deteriorated QOL more profoundly than OAB or UAB alone, promoting the health-care seeking behavior of the participants.
Figure 1 Figure 1
Figure 2 Figure 2
References
  1. Mancini V, et al. Neurourol Urodyn. 2020;39 Suppl 3:S50-S59.
  2. Coyne KS, et al. BJU Int. 2008;101:1388-1395.
  3. Chapple CR et al. Neurourol Urodyn. 2018;37:2928-2931.
Disclosures
Funding This study was supported by the 50th Anniversary Project of the Japanese Continence Society. Clinical Trial No Subjects Human Ethics Committee This study was approved by the Nihon University Itabashi Hospital Clinical Research Judging Committee and was approved on May 10, 2023 (ID 2023-04). Helsinki Yes Informed Consent Yes
25/08/2024 13:35:58